Renheng Pharmaceutical

Renheng Pharmaceutical is a high-tech enterprise located in Guangzhou Science City and a listed company on the New Third Board. The company has 2,600 square meters of R&D space, and its R&D team is composed of professionals with doctoral, master's, and bachelor's degrees in pharmacy. Driven by R&D and innovation, the company adheres to the philosophy of 'improving the clinical accessibility of high-quality drugs.' Leveraging extensive experience in drug development, pharmaceutical engineering, biotechnology, and the pharmaceutical market, it specializes in pharmaceutical product R&D, consistency evaluation, and drug import registration services. The company implements the national drug marketing authorization holder system to provide the public with high-quality and effective drugs. Renheng Pharmaceutical focuses on the R&D of chemically modified drugs and generics, with core products in eye drops, cardiovascular and cerebrovascular drugs, and drugs for diabetes treatment and prevention. It introduces advanced foreign technologies and actively cooperates with renowned domestic universities to optimize drug R&D and production processes and explore the added value of core products. Since its establishment, Renheng Pharmaceutical has placed great emphasis on product project initiation, R&D process control, and standardized experimental operation procedures. It manages R&D work in a standardized manner and has established a comprehensive quality assurance system, providing a solid foundation for win-win cooperation with clients. The company has expanded its business through multiple channels and enriched its customer base, establishing long-term and stable cooperation with multiple listed pharmaceutical companies at home and abroad. Meanwhile, the company actively carries out industry-university-research project cooperation with Southern Medical University, Sun Yat-sen University, Qingdao University, and Chengdu University. This cooperation model not only leverages the advantages of each party but also continuously supplies the company with outstanding graduates, providing strong talent assurance for the sustained development and continuous improvement of the company's R&D capabilities. Company honors: In 2015, Renheng Pharmaceutical was awarded the title of High-Tech Enterprise; in 2016, Renheng Pharmaceutical passed the construction of Guangzhou R&D Institution and successfully listed on the New Third Board (stock code: 870511); in 2017, Renheng Pharmaceutical passed the national intellectual property standard implementation certification and successfully passed the acceptance of the 2017 Science and Technology Innovation Enterprise Development Special Project (Special Project for Technology-Based Small and Medium-Sized Enterprise Innovation). In 2018, Renheng Pharmaceutical passed the high-tech enterprise re-examination and was again recognized as a 'High-Tech Enterprise'; in 2019, Renheng Pharmaceutical was awarded the title of 'Contract-Abiding and Credit-Worthy Enterprise' for three consecutive years.